Literature DB >> 25459069

Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07).

Jeong Il Yu1, Doo Ho Choi2, Seung Jae Huh1, Sung Ja Ahn3, Ji Shin Lee4, Kyung Hwan Shin5, Youngmee Kwon5, Yong Bae Kim6, Chang-Ok Suh6, Jin Hee Kim7, Jihyoung Cho8, In Ah Kim9, Jong Hoon Lee10, Won Park1.   

Abstract

BACKGROUND: This retrospective study was performed to investigate the need for management modification in MBC according to evaluation of characteristics and failure patterns compared with IDC. PATIENTS AND METHODS: We performed this multicenter study taking MBC and randomly assigned IDC cases matched for age (± 3 years), pathologic stage (T and N), locoregional treatment methods (surgery with or without radiation therapy), and period of treatment (± 6 months) that occurred from January 1999 to November 2011 in the 6 institutions of the Korean Radiation Oncology Group.
RESULTS: A total of 144 female MBC patients were enrolled. The median follow-up was 51 months (range, 1-186 months). The rates of positivity for estrogen receptor (P < .001), progesterone receptor (P < .001), and HER2 (P = .007) were significantly lower in MBC patients. During follow-up, recurrence developed in 22 (15.3%) MBC and 6 (4.2%) IDC patients (P = .002). The median time to recurrence of MBC and IDC was 15 months and 24 months, respectively. Most instances of recurrence in MBC developed in the triple-negative (TN) subgroup (TN-MBC). In particular, locoregional recurrence developed exclusively in the TN-MBC subgroup. In the TN-MBC subgroup, the number of risk factors (pT2-3, N1-3) was related to significant differences in overall survival (P = .001) and recurrence-free survival (P < .001).
CONCLUSION: The MBC patients had a higher rate of TN, poorer differentiation, and a higher recurrence rate than did the IDC patients. Considering the unique characteristics and failure patterns, it is necessary to modify the current management guidelines for MBC.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Case-control study; Invasive ductal carcinoma; Metaplastic breast cancer; Pattern of failure; Prognostic factor

Mesh:

Substances:

Year:  2014        PMID: 25459069     DOI: 10.1016/j.clbc.2014.10.002

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  12 in total

1.  Combined Use of Mammography and FNA Eliminates Pitfalls in the Management of Metaplastic Breast Carcinoma.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Schizas; Anargyros Bakopoulos; Demetrios Moris; Gabriela-Monica Stanc; Anastasios Tentolouris; Soumphi Nassar; Charitini Salla
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

2.  Metaplastic carcinoma of the breast: Clinicopathological features and treatment outcomes with long-term follow up.

Authors:  Aron Gortman; Noel J Aherne; Justin Westhuyzen; Julan V Amalaseelan; Patrick M Dwyer; Matthew Hoffmann; Andrew T Last; Thomas P Shakespeare
Journal:  Mol Clin Oncol       Date:  2021-07-01

3.  Metaplastic Carcinoma Breast: A Clinical Analysis of Nine Cases.

Authors:  Manashi Ghosh; A Muneer; Vinita Trivedi; Kaustav Mandal; Santosh Shubham
Journal:  J Clin Diagn Res       Date:  2017-08-01

4.  Research on the Role of Combined Chemotherapy and Radiotherapy in Patients With N+ Non-Metastatic Metaplastic Breast Carcinoma: A Competing Risk Analysis Model Based on the SEER database, 2000 to 2015.

Authors:  Yifei Ma; Zejian Yang; Yihan Gao; Kunlong Li; Pei Qiu; Heyan Chen; Shengyu Pu; Bo Wang; Can Zhou
Journal:  Front Oncol       Date:  2021-01-22       Impact factor: 6.244

5.  The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma.

Authors:  San-Gang Wu; Shi-Ping Yang; Wen-Wen Zhang; Jun Wang; Chen-Lu Lian; Yong-Xiong Chen; Zhen-Yu He
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

6.  Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.

Authors:  Jinqian Mao; Jin Hu; Yanting Zhang; Jian Shen; Fang Dong; Ximeng Zhang; Jie Ming; Tao Huang; Xiaoqin Run
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

7.  The Present and Future Opportunities of the Rare Cancer Network: An International Consortium for Advancement of Oncologic Care.

Authors: 
Journal:  Rare Tumors       Date:  2015-10-02

8.  Development of ipsilateral chest wall spindle cell carcinoma in a patient with invasive ductal breast carcinoma during postoperative adjuvant therapy: A case report.

Authors:  Kaifu Li; Hua Kang; Yajun Wang; Tao Hai; Bixiao Wang
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

9.  The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database.

Authors:  Yongfeng Li; Meng Chen; Barbara Pardini; Mihnea P Dragomir; Anthony Lucci; George A Calin
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531

10.  Management of the axilla in metaplastic breast carcinoma.

Authors:  Brittany L Murphy; Robert T Fazzio; Tanya L Hoskin; Katrina N Glazebrook; Michael G Keeney; Elizabeth B Habermann; Tina J Hieken
Journal:  Gland Surg       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.